Abbott Laboratories (ABT) shares soared 5.28% in pre-market trading on Wednesday after the healthcare giant reported better-than-expected first-quarter earnings and reaffirmed its full-year 2025 guidance.

The company posted adjusted earnings per share of $1.09, surpassing analysts' estimates of $1.07. Abbott's strong performance was driven by robust growth in its medical devices segment, particularly in diabetes care, where sales of continuous glucose monitors increased 18.3% year-over-year. The nutrition segment also showed solid growth, with global sales rising 3.8% on a reported basis.

Despite ongoing global economic uncertainties, Abbott maintained its full-year 2025 guidance, projecting adjusted earnings per share of $5.05 to $5.25 and organic sales growth of 7.5% to 8.5%. The company's ability to navigate through challenging market conditions while delivering strong results across its diversified portfolio has boosted investor confidence, contributing to the significant pre-market stock surge.